[DOI] [PMC free article] [PubMed] [Google Scholar] 161.Srivastava S., Kashiwaya Y., King M.T., Baxa U., Tam J., Niu G., Chen X., Clarke K., Veech R.L
Requena-Ibanez JA, et al
Rationale for Semaglutide in MASH: Impact on Metabolism and Liver Fat Data from the ongoing phase 3, multicentre, placebocontrolled ESSENCE trial involving patients with biopsyconfirmed MASH and liver fibrosis (stage F2 or F3) demonstrated that subcutaneous semaglutide 2.4 mg/week not only improves steatosis but also reduces necroinflammation, hepatocellular ballooning and fibrosis [8]
if more than 5 days have passed, they should skip that dose and resume with the next scheduled injection
After injection, the active compound enters systemic circulation and distributes throughout the body